China's corneal transplant field has recently seen dual benefits: on one hand, a new generation of bioengineered corneas (such as acellular porcine corneal stroma) has demonstrated comparable efficacy to traditional donor corneas in clinical trials, with a 12-month graft survival rate of 92%; on the other hand, the National Health Commission has issued the "Regulations on Corneal Donation and Transplantation Management (2025 Edition)", which for the first time incorporates donor source traceability, quality grading, and cross-regional allocation into mandatory standards, increasing the national donor utilization rate to 78% and shortening the average waiting time from 18 months to 10 months.
The above data comes from the 2025 Annual Report of the Chinese Ophthalmological Society, marking China's shift from technological catch-up to systematic development in corneal transplantation.
Background and Significance
Corneal blindness is the second leading cause of blindness in China, with approximately 4 million patients awaiting transplantation, but traditional donors are severely scarce. This technological breakthrough focuses on two points: first, the clinical promotion of artificial corneas (such as the Micah artificial cornea) and bioengineered corneas to reduce dependence on cadaveric donors; second, the digitalization of donor management, achieving real-time matching through the National Eye Bank Information Platform, with cities like Shanghai and Beijing already enabling cross-provincial donor allocation within 48 hours. These advancements not only improve domestic surgical accessibility but also provide a Chinese model for setting Asian corneal transplant standards.
Significance for International Patients
For overseas patients, especially those from regions with more severe donor shortages, China's corneal transplant cost and efficiency advantages are evident. For example, at a Shanghai tertiary hospital partnered with MedCarePlus, the total cost of bioengineered corneal transplantation is approximately 40% of that in Western countries, with a comprehensive postoperative follow-up system, including remote visual function monitoring and complication management. Additionally, standardized donor sources mean a lower risk of infectious disease transmission, and international patients can request to view donor testing reports (including 6 indicators such as HIV and hepatitis B).
How MedCarePlus Helps
MedCarePlus provides full-process support for international patients undergoing corneal transplantation: preoperatively, the cost estimator tool clarifies total expenses and arranges online ophthalmic consultations to assess suitability for bioengineered corneas; intraoperatively, it coordinates partner hospitals to prioritize surgical scheduling, reducing the average time from admission to surgery to 3 days; postoperatively, it offers a 6-month follow-up plan, including vision checks at local partner institutions and guidance on immunosuppressive medication. To initiate treatment, you can obtain dedicated medical advisor support through Contact Us.
Related Reading: Overview of Partner Hospitals in Shanghai